Status:
COMPLETED
Telbivudine Versus the Combination of Telbivudine and Valtorcitabine in Patients With Chronic Hepatitis B
Lead Sponsor:
Novartis
Collaborating Sponsors:
Novartis Pharmaceuticals
Conditions:
Hepatitis B
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
This study is being conducted to compare the effectiveness of the combination of valtorcitabine and telbivudine to telbivudine alone in patients with chronic hepatitis B.
Eligibility Criteria
Inclusion
- Clinical history compatible with compensated chronic hepatitis B
- Other protocol-defined inclusion criteria may apply.
Exclusion
- Patient is pregnant or breastfeeding
- Patient is co-infected with hepatitis C virus, hepatitis D virus or HIV
- Patient has previously received lamivudine, adefovir dipivoxil or an investigational anti-hepatitis B virus (HBV) nucleoside or nucleotide at anytime.
- Other protocol-defined exclusion criteria may apply.
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
End Date :
May 1 2007
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT00128544
Start Date
May 1 2005
End Date
May 1 2007
Last Update
June 16 2017
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Pokfulam, Hong Kong
2
Auckland, New Zealand
3
Singapore, Singapore